Daily Newsletter

22 February 2024

Daily Newsletter

22 February 2024

Aptar acquires digital health company Healint

The acquisition forms part of Aptar Digital Health's plan to expand its portfolio in the neurology sector.

Archana Rani February 22 2024

Aptar Digital Health has announced the acquisition of Healint, a Singapore-based company known for its virtual clinical studies and patient support applications.

The acquisition forms part of Aptar Digital Health's efforts to expand its portfolio in the neurology sector and bolster its global digital health deployment capabilities.

Financial terms of the deal were undisclosed.

Established in 2013, Healint is known for its multimodal health tracking and Quality of Life (QoL) data collection, utilising both self-reported and sensor data, interpreted through artificial intelligence (AI).

The company’s first patented migraine-tracking mobile app, Migraine Buddy, has more than three million registered users.

Aptar Digital Health president Sai Shankar said: “We are excited to welcome the Healint team and expand Aptar Digital Health’s product portfolio and capabilities to clinical trial management.

“With Healint, we now have the in-house expertise to cover the entire lifecycle of a drug, positioning Aptar Digital Health as a prominent leader in digital health for Central Nervous System conditions.”

The integration of Healint's capabilities, including AI-driven data collection and analysis, digital diagnostics, and patient community management, will provide additional value to Aptar's pharmaceutical clients.

The company plans to scale Healint’s platform to additional neurology and immunology indications and enhance its services with new clinical trial management tools.

Healint CEO and founder François Cadiou said: “We are delighted to join the Aptar Digital Health team to better serve patients, healthcare professionals and pharmaceutical companies.

“This acquisition will accelerate the development of our AI-powered precision medicine SaMD designed to augment existing treatment, thanks to unique datasets and scientific expertise.”

Recently, Aptar signed an enterprise agreement with Biogen to develop digital health solutions to enhance care for patients with neurological and rare diseases.

Uncover your next opportunity with expert reports

Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.

Newsletters by sectors


Sign up to the newsletter: In Brief

Your corporate email address *
First name *
Last name *
Company name *
Job title *
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.